Genes Associated with Fat Metabolism Could Increase Kidney Cancer Risk
November 17, 2008
WASHINGTON, D.C. - A team of international scientists has identified three genes associated with the body's processing of fats that may increase susceptibility to kidney cancer. The findings were presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research.
The researchers found that variations within three genes associated with lipid peroxidation - the process of breaking down fats and lipids when exposed to oxygen - could increase a person's risk of kidney cancer. Scientists have suspected lipid peroxidation as a unifying mechanism through which risk factors such as obesity, hypertension and smoking could damage kidney tissue and lead to kidney cancer.
"Obesity, hypertension and smoking have been the only established risk factors for kidney cancer, but they account for only 50 percent of cases," said lead author Lee E. Moore, Ph.D., M.P.H., an epidemiologist and investigator at the National Cancer Institute. "Our study suggests that common genetic variation may account for some of the increased risk in the other half of cases. This is the first and largest study of renal cell cancer to evaluate the influence of these genes."
For the study, Moore and a group of international colleagues studied blood DNA from 987 kidney cancer patients and 1,298 healthy counterparts living in Central and Eastern Europe, which have the highest rates of kidney cancer worldwide. The scientists analyzed DNA for hundreds of variations within 38 genes known to play a role in lipid peroxidation, inflammation and oxidative stress.
Variants of two genes were associated with increased risk of kidney cancer: nitric oxide synthase 2A (NOS2A), which increases levels of nitric oxide, a chemical that promotes free radical damage to cells; and prostaglandin-endoperoxide 2 (PTGS2), which produces prostaglandins, compounds that cause inflammation. Variants of a third gene, apolipoprotein E1 (ApoE1), which helps break down and remove triglycerides from the blood and liver, were associated with a reduction in risk for the disease.
Replication and fine mapping studies will be required to confirm these findings, Moore said. She is planning another study to look at these genetic variants among white and African-American kidney cancer patients in the United States.
Kidney cancer, one of the 10 most common forms of the disease, has been increasing in incidence in the United States and worldwide since the 1970s, Moore said.
# # #
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and 80 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. The AACR's most recent publication and its sixth major journal, Cancer Prevention Research, is dedicated exclusively to cancer prevention, from preclinical research to clinical trials. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
In Washington, D.C., Nov. 16-18: 301-965-5422